Morphea is a form of scleroderma, but it is not the same disease most people fear when they hear that word. Scleroderma is an umbrella term covering two distinct conditions: localized scleroderma (morphea) and systemic sclerosis. Morphea affects only the skin and nearby tissues. Systemic sclerosis affects the skin and internal organs. These are separate diseases, and morphea does not turn into systemic sclerosis.
The confusion between the two causes real anxiety for patients. Because they share a name, many people diagnosed with morphea worry they have a progressive, organ-threatening illness. Some experts now recommend dropping the term “localized scleroderma” entirely and using only “morphea” to prevent this misunderstanding.
How Morphea Differs From Systemic Sclerosis
The core distinction is straightforward: morphea stays in the skin, while systemic sclerosis can involve the lungs, heart, kidneys, gastrointestinal tract, and blood vessels. About two-thirds of all people diagnosed with scleroderma have the localized form (morphea), making it the more common of the two.
Several hallmark symptoms of systemic sclerosis simply do not occur in morphea. Raynaud’s phenomenon, where fingers and toes turn white or blue in cold temperatures, is often the first sign of systemic sclerosis but is absent in morphea. Sclerodactyly, the tight thickening of skin on the fingers, and fingertip ulcers are also exclusive to systemic disease. If you have morphea and none of these symptoms, that pattern is expected and reassuring.
One point bears repeating because it matters so much to people who’ve just been diagnosed: localized scleroderma does not evolve into systemic scleroderma. Multiple large reviews confirm this. They are distinct conditions from the start, not stages of the same disease.
What Happens in the Skin
Morphea begins with immune system dysfunction. White blood cells, particularly a type called T helper cells, infiltrate the skin and trigger inflammation. These cells produce signaling molecules that ultimately push fibroblasts (the cells responsible for building connective tissue) into overdrive, generating excess collagen. The result is patches of skin that become thickened, hardened, and discolored.
The disease tends to move through three phases. First, an inflammatory phase where skin may look red or purplish and feel warm or swollen. Second, a fibrotic phase where the skin hardens and thickens. Third, an atrophic phase where the hardness gradually fades over two to five years, leaving behind thinner, sometimes wrinkled skin with changes in pigmentation. During this final phase, the skin may appear darker or lighter than surrounding areas, and hair or sweat glands in the affected spot may not return.
Types of Morphea
Morphea isn’t a single presentation. It appears in several forms that vary in depth, location, and severity.
- Plaque morphea is the most common type, producing oval or round patches of hardened skin on the trunk or limbs. These are generally considered low severity.
- Linear morphea forms band-like streaks, often on a limb or on one side of the face or scalp. In children, this type can restrict growth of the underlying bone and muscle if left untreated.
- Generalized morphea involves multiple plaques spread across several body regions.
- Deep morphea extends below the skin surface into the fat, fascia, or muscle layer, sometimes causing visible indentations.
Linear and deep forms carry the highest risk of lasting physical changes. In children, unchecked linear morphea on a limb can lead to joint contractures, limb length differences, and soft tissue loss. On the face or scalp, it can cause hair loss and visible tissue thinning.
Beyond the Skin
Although morphea is defined as a skin-limited disease, some patients do experience symptoms outside the skin. These extracutaneous manifestations are uncommon and look different from systemic sclerosis. They can include joint pain, muscle involvement, and in rare cases of head and face linear morphea, neurological findings. The key distinction is that morphea does not attack the lungs, kidneys, or heart the way systemic sclerosis can.
Who Gets Morphea
Morphea is relatively uncommon, with an estimated incidence of about 1.4 per 10,000 people per year in the United States. It strongly favors women. In one large U.S. database study, roughly 90% of patients were female. Rates climb substantially with age in women, peaking around age 64, which largely explains the condition’s well-known female predominance. The average age at diagnosis in that study was between 47 and 55, though morphea can also appear in children, where linear forms are especially common.
How It’s Diagnosed
Diagnosis is primarily clinical, based on the appearance and feel of the skin lesions. A skin biopsy can confirm the diagnosis by revealing the characteristic pattern of collagen buildup and inflammatory cell infiltration. Blood tests for autoimmune antibodies (particularly ANA) are sometimes positive, especially in generalized morphea, but a positive antibody test alone doesn’t mean you have systemic sclerosis. The absence of Raynaud’s, fingertip changes, and internal organ involvement is what clinically separates morphea from its systemic counterpart.
Treatment by Severity
Treatment depends on which type of morphea you have and how deep or widespread it is. Superficial plaque morphea, the mildest form, is typically managed with topical treatments: mid- to high-potency steroid creams, a vitamin D-based cream called calcipotriol, or a prescription ointment called tacrolimus. Phototherapy (controlled UV light exposure) is sometimes added.
Linear, deep, and generalized morphea require stronger treatment. Methotrexate, a medication that calms the overactive immune response, is the standard first-line systemic therapy. It’s often paired with a short course of oral steroids as “bridge therapy” to control inflammation while methotrexate takes effect over several weeks. For cases that don’t respond, alternative immune-suppressing medications or, in severe situations, biologic therapies may be considered.
The goal of treatment is to stop the inflammatory phase before it causes permanent tissue changes. Once skin has moved into the atrophic phase with thinning and pigment changes, those effects are largely irreversible, though the hardness itself tends to soften over time. Active disease typically runs its course over months to years. Sclerosis often continues to improve slowly, even after treatment is stopped, though slight increases in skin thinning may continue as the hardened areas soften.